Hemoglobin News and Research

RSS

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.

14 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Shriners Hospitals for Children uses Masimo SpHb during selected surgeries

The healthcare professionals at Shriners Hospitals for Children - Honolulu, which perform hundreds of orthopaedic surgeries on children each year, are using the latest in medical technology from Masimo to noninvasively monitor patient blood levels during selected surgeries.

31 Aug 2011

Hurricane Irene affects supplies of several blood types

New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, is following the emergency declarations of Mayor Bloomberg and other tri-state public officials with an emergency appeal for blood donors. The supply of several blood types, including O-negative ("universal donor") blood, which is normally maintained at the three-to-five-day inventory level, has dropped below the two-day minimum level.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Researchers exploring how microwaves may be used to treat malaria

The New York Times describes a research proposal to investigate the use of low-level microwaves to treat malaria that has received a $1 million grant from the Bill & Melinda Gates Foundation.

24 Aug 2011

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.

12 Aug 2011

YASOO Health launches grape flavored liquid iron supplement for children

YASOO Health Inc, Morrisville, NC has introduced IronUp, a Liquid Iron Supplement specifically formulated to supplement the levels of dietary iron for infants and children who do not receive adequate amounts in their diets.

10 Aug 2011

Masimo lifts voluntary product recall of Pronto-7 noninvasive finger sensor

Masimo announced today that it has lifted the voluntary product recall the company imposed on the noninvasive finger sensor of its Pronto-7 handheld device to improve the product's performance in low ambient temperatures. The Pronto-7 and new finger sensors are pending FDA 510(k) clearance in the U.S.

8 Aug 2011

Mobile health software effectively helps manage diabetes

An interactive computer software program appears to be effective in helping patients manage their Type 2 diabetes using their mobile phones, according to a new study by University of Maryland School of Medicine researchers.

1 Aug 2011

Mobile health technology may help patients manage Type 2 diabetes

1 Aug 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

Simple dental algorithm can effectively identify patients with unrecognized diabetes

In a study, Identification of unrecognized diabetes and pre-diabetes in a dental setting, published in the July 2011 issue of the Journal of Dental Research, researchers at Columbia University College of Dental Medicine found that dental visits represented a chance to intervene in the diabetes epidemic by identifying individuals with diabetes or pre-diabetes who are unaware of their condition.

15 Jul 2011

Patient-centered medical home boosts diabetes outcomes, health

A health-care delivery model called patient-centered medical home (PCMH) increased the percentage of diabetes patients who achieved goals that reduced their sickness and death rates, according to health researchers.

14 Jul 2011